- $44.61bn
- $58.66bn
- $16.31bn
IQVIA lifts annual profit forecast as pharma spending improves
Iqvia Falls After Reporting First: quarter results
IQVIA beats Q1 revenue estimates, raises 2026 adj. EPS outlook
Brief: IQVIA Q1 Adjusted EPS USD 2.9 Vs. IBES Estimate USD 2.82
Novo Nordisk's weight-loss pill boom faces price war test
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
RCS - Envision Pharma Grp - Envision Pharma Group Announcement
U.S. RESEARCH ROUNDUP-3M, CME Group, Transdigm Group
AI-led selloff in contract research firms may be misjudging disruption risk
Brief: IQVIA Unveils IQVIA.AI, A Unified Agentic AI Platform Powered By Nvidia To Improve Efficiency And Decision Making Across Life Sciences
Iqvia Rises As It Buys Charles River's Early: stage drug research assets
Charles River raises annual profit view as it sells underperforming assets
Brief: Iqvia Signs Agreement To Acquire Drug Discovery Assets From Charles River Laboratories, Expanding End-To-End Drug Discovery Capabilities
Live Markets: 'AI is not coming' for Charles River, rather could benefit the company, Barclays says
Charles River forecasts upbeat 2026 profit on improved demand for drug development services (updated)
U.S. RESEARCH ROUNDUP-Brixmor Property, Mohawk Industries, UDR
U.S. RESEARCH ROUNDUP-Brixmor Property, Mohawk Industries, UDR
Brief: Iqvia And Duke Clinical Research Institute Announce Strategic Collaboration To Advance Clinical Research In Obesity And Related Conditions
U.S. RESEARCH ROUNDUP-Amazon, Estée Lauder, Ralph Lauren